Using Patent Data to Assess the Value of Pharmaceutical Innovation

&
Journal of Law, Medicine and Ethics 37 (2):176-183 (2009)
  Copy   BIBTEX

Abstract

Though many more patents emerge from industry sources, drug-related patents generated in the non-profit setting appear to have greater importance than patents arising from the commercial sector, which helps demonstrate the value non-profit research institutions can have in driving drug development

Categories

Keywords

Reprint years

DOI

10.1111/j.1748-720x.2009.00364.x

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,386

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

What are the costs and benefits of patent systems?Hazel V. J. Moir - unknown
Pharmaceutical innovation and the burden of disease in developing and developed countries.Frank R. Lichtenberg - 2005 - Journal of Medicine and Philosophy 30 (6):663 – 690.
Incentivizing access and innovation for essential medicines: A survey of the problem and proposed solutions.Michael Ravvin - 2008 - Public Health Ethics 1 (2):110-123.
Patents, Innovation, and Privatization: Commentary on: “Data Management in Academic Settings: An Intellectual Property Perspective”.Ramona C. Albin - 2010 - Science and Engineering Ethics 16 (4):777-781.
Preemption Games with Private Information.Hugo Hopenhayn - unknown
Patent agent.Justine Pila - unknown
The constant gardener revisited: The effect ofsocial blackmail on the marketing concept,innovation, and entrepreneurship. [REVIEW]Morgan P. Miles, Linda S. Munilla & Jeffrey G. Covin - 2002 - Journal of Business Ethics 41 (3):287 - 295.
Uk's national patent strategies and the features of its patent abuses: Some scattered thoughts.Neethu Rajam - unknown
Ethical considerations in the use of direct-to-consumer advertising and pharmaceutical promotions: The impact on pharmaceutical sales and physicians. [REVIEW]R. Stephen Parker & Charles E. Pettijohn - 2003 - Journal of Business Ethics 48 (3):279-290.
Pharmaceutical medicine.D. M. Burley & Theodore Barker Binns (eds.) - 1985 - Baltimore, Md., U.S.A.: E. Arnold.
Is Marketing the Enemy of Pharmaceutical Innovation?Kalman Applbaum - 2009 - Hastings Center Report 39 (4):13-17.
Patent rights or patent wrongs? The case of patent rights on AIDS drugs.Samantha Byrne, Paul Davey, Kirsti McFarlane, John O'Brien & Craig Templeton - 2006 - Business Ethics, the Environment and Responsibility 15 (3):299–305.
Before the house of lords.Justine Pila - unknown
Business Ethics of Innovation.Gerd Hanekamp - 2005 - Poiesis and Praxis 3 (4):310-314.
The european patent convention.Justine Pila - unknown

Analytics

Added to PP
2010-09-13

Downloads
27 (#576,320)

6 months
8 (#347,798)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Pharmaceutical Innovation: Law & the Public's Health.Kevin Outterson - 2009 - Journal of Law, Medicine and Ethics 37 (2):173-175.

Add more citations

References found in this work

No references found.

Add more references